Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients. 2009

Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan. tnishida@med.nagoya-u.ac.jp.

Bone marrow transplantation from unrelated donors (UR-BMT) has been considered to be effective for patients with hematological malignancies who have no suitable related donor. However, disparities of HLA between a recipient and a donor increase the risk of severe acute graft-versus-host disease (GVHD). We evaluated GVHD prophylaxis using tacrolimus and methotrexate for HLA-A, B, or DRB1 genotypically mismatched UR-BMT. Fifty-five patients were enrolled in this study. The incidence of grade III to IV acute GVHD was 23.6% for all patients. No significant difference in the incidence of grade III to IV acute GVHD was observed between HLA-A or B 1 locus mismatch transplantation (18.8%) and HLA-DRB1 1 locus mismatch transplantation (16.7%) (P = 0.96). The incidence of chronic GVHD was 71.7%. Disease-free survival at 5 years was 53.2% for patients with standard risk disease and 24.5% for patients with high-risk disease. Patients with chronic GVHD exhibited better disease-free survival than those without chronic GVHD (53.2 vs. 30.9%, P = 0.011). Twenty patients (36.4%) had a relapse of leukemia and 14 of them died of recurrent leukemia. This study indicates tacrolimus and methotrexate can lower the risk of severe acute GVHD after HLA-A, B, or DRB1 genotypically 1 locus mismatched UR-BMT.

UI MeSH Term Description Entries
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002423 Cause of Death Factors which produce cessation of all vital bodily functions. They can be analyzed from an epidemiologic viewpoint. Causes of Death,Death Cause,Death Causes
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
August 1998, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
September 2000, Blood,
Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
October 1998, Blood,
Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
October 1999, Bone marrow transplantation,
Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
October 2009, Blood,
Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
December 1996, Blood,
Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
February 1995, Bone marrow transplantation,
Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
September 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
September 2003, Blood,
Tetsuya Nishida, and Tohru Murayama, and Hisamaru Hirai, and Shinichiro Okamoto, and Hiroshi Sao, and Masamichi Hara, and Heiwa Kanamori, and Yoshiko Atsuta, and Keitaro Matsuo, and Yasuo Morishima, and Yoshihisa Kodera
October 2022, Transplantation and cellular therapy,
Copied contents to your clipboard!